TLC and 3SBio Announce Acceptance of Marketing Authorization Application for Ampholipad™ in China

TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, in conjunction with 3SBio, today announced that th …
( read original story …)


Search your Hotel